Bayer plans cooperation agreement with Boehringer Ingelheim
The planned cooperation agreement will govern the co-marketing of the antihypertensive drug in Germany, Scandinavia and Switzerland. Bayer provisionally plans to launch the product in January 2003. Telmisartan is protected by patent until 2012.
"This product suits our European portfolio of cardiovascular drugs extremely well. Furthermore, telmisartan will allow our field force to impressively demonstrate their expertise. The cooperation agreement is therefore an ideal, complementary fit for both companies," said Dr. Wolfgang Plischke, Head of the Pharmaceuticals Division of Bayer HealthCare, Bayer AG.
"Telmisartan has an excellent medical profile and a high priority for Boehringer Ingelheim. That is why we will exploit its full potential in all markets and territories by cooperating with strong partners. In addition to our co-promotion / co-marketing strategies with Abbott and GlaxoSmithKline in certain countries, we are happy to work with Bayer in Germany, Scandinavia and Switzerland," said Prof. Rolf Krebs, Chairman of the Board of Managing Directors of Boehringer Ingelheim.
Bayer and Boehringer will continue to look for opportunities to extend their collaborative work on telmisartan to other countries.
Telmisartan is an angiotensin II antagonist, a class of drugs characterized by the strongest growth in the antihypertensives market.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.